JHVEPhoto Abiomed, a division of Johnson & Johnson (NYSE: JNJ ) MedTech, said that an investigational device exemption (IDE) study of the Impella ECP transvalvular axial flow pump met its primary endpoint, a measure of MACCE (Major Adverse Cardiac and Cerebrovascular Events). At.
Back to Health Page
